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Background: Nutritional supplements designed to increase adenosine 5′-triphosphate (ATP) concentrations are
commonly used by athletes as ergogenic aids. ATP is the primary source of energy for the cells, and
supplementation may enhance the ability to maintain high ATP turnover during high-intensity exercise. Oral ATP
supplements have beneficial effects in some but not all studies examining physical performance. One of the
remaining questions is whether orally administered ATP is bioavailable. We investigated whether acute
supplementation with oral ATP administered as enteric-coated pellets led to increased concentrations of ATP or its
metabolites in the circulation.
Methods: Eight healthy volunteers participated in a cross-over study. Participants were given in random order
single doses of 5000 mg ATP or placebo. To prevent degradation of ATP in the acidic environment of the stomach,
the supplement was administered via two types of pH-sensitive, enteric-coated pellets (targeted at release in the
proximal or distal small intestine), or via a naso-duodenal tube. Blood ATP and metabolite concentrations were
monitored by HPLC for 4.5 h (naso-duodenal tube) or 7 h (pellets) post-administration. Areas under the
concentration vs. time curve were calculated and compared by paired-samples t-tests.
Results: ATP concentrations in blood did not increase after ATP supplementation via enteric-coated pellets or
naso-duodenal tube. In contrast, concentrations of the final catabolic product of ATP, uric acid, were significantly
increased compared to placebo by ~50% after administration via proximal-release pellets (P = 0.003) and
naso-duodenal tube (P = 0.001), but not after administration via distal-release pellets.
Conclusions: A single dose of orally administered ATP is not bioavailable, and this may explain why several studies
did not find ergogenic effects of oral ATP supplementation. On the other hand, increases in uric acid after release of
ATP in the proximal part of the small intestine suggest that ATP or one of its metabolites is absorbed and
metabolized. Uric acid itself may have ergogenic effects, but this needs further study. Also, more studies are needed
to determine whether chronic administration of ATP will enhance its oral bioavailability.
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Nutritional supplements designed to increase adenosine
5′-triphosphate (ATP) concentrations are commonly
used by athletes as ergogenic aids. ATP is the primary
source of energy for the cells, and supplementation may
enhance the ability to maintain high ATP turnover dur-
ing high-intensity exercise. ATP is also released from
cells to act as a local regulator of neurotransmission, in-
flammation, and nociception via interaction with puri-
nergic receptors [1,2]. ATP is present in substantial
concentrations in a number of foods (e.g. meat, soy,
mushrooms) [3] and in breast milk [4,5]. Furthermore,
capsules containing ATP are currently registered in
France for the treatment of low back pain of muscular
origin, and supplements containing ATP are marketed
on the internet for various purposes including the restor-
ation of energy.
Oral ATP supplements have beneficial effects in some but
not all studies examining physical performance. In an ex-
perimental study by Jordan et al. [6], three groups of nine
healthy men received ATP (150 or 225 mg) or placebo for
14 days. Physical performance and muscular strength were
positively affected. Another study investigated the effects
of supplementation with an ATP-containing registered
drug for 30 days (AtépadèneW, 90 mg daily) [7,8]. The
questionnaire-based outcome indicated that it provided
benefit to patients with subacute low back pain. In contrast
to these beneficial findings, Herda et al. [9] found no
improvements in muscle strength, power output, or en-
durance after supplementation of 24 healthy men with a
commercially available treatment intended to increase
ATP. The authors suggested that the lack of an effect in
this double-blind, placebo-controlled crossover trial,
might be caused by breakdown of ATP in the gastro-
intestinal tract. Because they did not collect blood sam-
ples from the participants, the authors could not verify
whether ATP concentrations in the blood circulation
had been altered as a result of supplementation [9].
Evidence on the oral availability of ATP supple-
ments is limited. In the study by Jordan et al. [6],
no changes in whole blood and plasma ATP concen-
trations were detected, but the dosages administered
were modest (225 mg or less). Animal studies report-
ing alterations in cardiac, vascular and pulmonary
function after 30 days of oral ATP supplementation,
also found no increases in systemic concentrations of
plasma or erythrocyte ATP [10,11]. However, the
concentration of ATP in plasma taken from the por-
tal vein of rats increased rapidly up to a 1000-fold
after instillation of ATP in de small intestine [11].
The identification of a number of nucleoside trans-
porters in the small intestine further suggested that
orally administered ATP may be absorbed and uti-
lized by the human body [12].We have previously shown that ATP is bioavailable after
intravenous administration in humans [13]. ATP concen-
trations in erythrocytes increased in a dose-dependent
manner by ~60% after 24 h of continuous infusion. We
now report the results of a randomized, placebo-
controlled, cross-over trial in 8 healthy humans, designed
to assess the oral bioavailability of an ATP nutritional sup-
plement. The ATP was administered as a single dose that
was high enough to enable its detection in whole blood
(5000 mg). Furthermore, an acid-resistant enteric coating
of the multi-particulate supplement was used to prevent
the degradation of ATP in the acidic environment of the
stomach. As a comparison, ATP was also directly instilled
in the small intestine via a naso-duodenal tube.
Methods
Study design
Subjects were examined on five occasions according to a
cross-over design. Two types of enteric coated pH-sensitive
multi-particulate supplements (from now on referred to as
pellets) were tested, one targeting the proximal part of the
small intestine, and one targeting the distal part. On days 0,
7, and 14, subjects received the following supplements in
random order: 5000 mg ATP as proximal-release pellets,
5000 mg ATP as distal-release pellets, or placebo proximal-
release pellets. The pellets were ingested with approxi-
mately 200 mL water acidified to pH< 5 with citric acid.
On days 21 and 28, subjects received in random order
5000 mg ATP dissolved in 100 mL water (30±4°C), or
water only (placebo), administered through a naso-
duodenal tube. The tube was inserted through the subjects’
nostril and placed in the stomach. To promote movement
of the tube through the pylorus into the duodenum, sub-
jects were asked to lay down on their right side. To verify
the tube’s position (either stomach or duodenum), gastro-
intestinal juice samples were taken by a syringe and tested
for their pH and color. Once pH was above 5 (±180 min
after insertion of the tube), and color was yellow, adminis-
tration started and the tube was removed 10 min later. The
study was approved by the Medical Ethics Committee of
Maastricht University Medical Centre. The study was car-
ried out according to the Helsinki Declaration for human
experiments.
Study population
Male and female subjects (18–60 years) received oral and
written information about the protocol and possible risks
before signing informed consent. Exclusion criteria were a
history of lung, heart, intestinal, stomach or liver disease,
use of prescription medication, smoking, drug use, dietary
restrictions, and pregnancy. Subjects abstained from pro-
ducts containing alcohol or caffeine and from purine-rich
foods, such as game, offal, sardines, anchovies and alcohol-
free beer for two days before each test day. Subjects fasted
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(4 p.m.), and refrained from any vigorous physical activity
starting 24 h before each test day. Subjects were allowed to
drink water starting 30 min after ATP or placebo
administration.
Materials
ATP disodium salt was purchased from Pharma Waldhof
GmbH, Düsseldorf, Germany. Adenosine 5′-diphosphate
(ADP) disodium salt, adenosine 5′-monophosphate (AMP)
sodium salt, adenine, inosine, hypoxanthine, uric acid and
nitric acid were purchased from Sigma Chemical Co.,
St. Louis, USA. Adenosine and lithium carbonate (Li2CO3)
were obtained from Fagron BV., Uitgeest, The Netherlands.
Perchloric acid (PCA) 70% solution in water was pur-
chased from Sigma-Aldrich, Steinheim, Germany. KOH,
KH2PO4, K2CO3, K2HPO3*3H2O and NaOH were
obtained from Merck, Darmstadt, Germany and 0.9% sa-
line from Braun, Melsungen, Germany. Bengmark-type
naso-duodenal tubes were from Flocare, Zoetermeer,
The Netherlands. NH4NO3 was obtained from Fluka,
Steinheim, Germany. Trichloroacetic acid (TCA) 20% solu-
tion in water was from Serva, Heidelberg, Germany. Citric
acid suitable for human consumption was obtained from
the pharmacy of Maastricht University Medical Centre.
Production of pellets
ATP pellets were produced at Ghent University, Faculty
of Pharmaceutical Science, Belgium as described by
Huyghebaert et al. [14], with minor modifications to ob-
tain an ATP concentration of >40% (wt:wt) after coat-
ing. Placebo pellets were produced in the same manner,
but without ATP. To verify the timing of intestinal release,
Li2CO3 (60 mg per administration) was added to the pel-
lets. The proximal-release pellets were coated with 30%
EudragitW L30D-55 (ATP or placebo pellets), and the
distal-release pellets (ATP only) were coated with 15%
EudragitW FS 30 D (Röhm Pharma, Darmstadt, Germany),
mixed with anionic copolymers of methacrylic acid and
ethylacrylate (1:1). After coating, the pellets were cured
overnight at room temperature at 60% (proximal-release
pellets) or 20% (distal-release pellets) humidity, packed in
aluminum foil sachets (VaporFlexW, LPS, NJ, USA),
sealed at their respective humidity and stored at room
temperature. Pellets were used within 3 months after
production.
Dissolution testing
To test whether the coating of the pellets was adequate,
a dissolution test (n= 3 for each type of coating) was per-
formed using the reciprocating cylinder method (USP
apparatus 3 from Bio-Dis, VanKel, NJ, USA) at a dip rate
of 21 dips per minute using 3 g pellets per vessel
(250 mL) with two consecutive media: 0.1 N HCl (37°C),and a 0.2 M KH2PO4 buffer (37°C) with a pH that was
adjusted to 6.5 for the proximal-release pellets, and pH
7.4 for the distal-release pellets. Samples were collected
after 2 h in HCl and after 2, 5, 10, 20, 30 and 60 min in
buffer as described in Huyghebaert et al. [14]. ATP and
metabolite concentrations were measured by HPLC sep-
aration and UV-analysis as previously described [15].
Sample collection during the intervention
Venous blood was collected from the antecubital vein
by a 20 gauge intravenous catheter (Terumo-Europe
NV, Leuven, Belgium), connected to a three-way stop-
cock (DiscofixW, Braun Melsungen AG, Melsungen,
Germany). Blood was collected into 4 mL EDTA tubes
(Venosafe, Terumo-Europe NV) by inserting a 21 gauge
multisample needle (Venoject Quick Fit, Terumo-Europe
NV) into the membrane of a closing cone (IN-Stopper,
Braun Melsungen AG) that was attached directly to the
stopcock. The anticoagulant EDTA inhibits the extracellu-
lar hydrolysis of ATP by Ca2+- and Mg2+-activated enzymes
such as plasma membrane-bound CD39 [16]. To avoid
clotting after each blood collection, approximately 1.5 mL
of heparinized (50 I.E./mL) 0.9% saline was used to rinse
the blood collection set-up. It was removed before the next
blood collection.
Three baseline blood samples were collected at 30, 20
and 10 min before administration. Starting 30 min after
pellet administration or 15 min after naso-duodenal admin-
istration, blood samples were collected every 15 min. Be-
tween 210 and 420 min (pellets) or 270 min (naso-
duodenal tube) after administration, samples were collected
every 30 min. Total volume collected per day was 92 mL.
After blood collection, the tubes were inverted three
times and put on ice. Five hundred μL of blood was
added to 500 μL ice-cold PCA (8% wt:v), vortex-mixed
and frozen in liquid nitrogen. Untreated plasma samples
(centrifugation at 3000 rpm, 10 min, 4°C) were collected
for assessment of lithium release from the pellets. All
samples were stored at -80°C awaiting analysis.
ATP measurement in whole blood by HPLC
Equipment, sample preparation and measurement condi-
tions have been previously described and validated [15].
Briefly, after thawing, the protein fraction was precipi-
tated (12,000 g, 10 min, 4°C) and 40 μL 2 M K2CO3 in
6 M KOH was added to 650 μL supernatant to neutralize
the pH. The resulting insoluble perchlorate was removed
by centrifugation (12,000 g, 10 min, 4°C), and 40 μL
supernatant was mixed with 160 μL 0.05 M phosphate
buffer pH 6.0 in HPLC vials.
Lithium measurement in plasma
To investigate the timing of pellet disintegration, plasma
concentrations of the lithium marker were measured using
Arts et al. Journal of the International Society of Sports Nutrition 2012, 9:16 Page 4 of 9
http://www.jissn.com/content/9/1/16a modified Trapp protocol [17]. Following thawing on
ice, 50 μL plasma was vortex-mixed with 10 μL
trichloroacetic acid (20% v:v) and centrifuged (14,000 rpm,
10 min) to precipitate the proteins. The supernatant was
diluted 20 times in 0.1 M nitric acid, which also served as
the blank. Two replicate measurements per sample were
performed on a SpectrAA 400 graphite tube atomic
absorption spectrophotometer (AAS) (Varian, Palo Alto,
CA, USA) with a lithium hollow-cathode lamp, operated
at 5 mA and a 1.0 nm slit. Peak height measurements at
670.8 nm wavelength were compared with values for
standards of known concentrations (ranging from 2 to
10 ng/mL). Initially, 20 μL sample and 5 μL modifier
solution (1.2 M NH4NO3) were injected into the top
hole of the graphite tube. Then, fluids were evaporated
at 95°C for 40 s and at 120°C for 10 s. The ash time was
15 s at 700°C, followed by atomization at 2300°C with a
3 s read time. If the obtained signal exceeded the stand-
ard concentration range (0–10 ng/mL), samples were
diluted with blank and measured again.
Statistical analysis
The area under the concentration vs. time curve (AUC)
was calculated using the linear trapezoidal rule from time
zero until the last time point of sampling t (AUC0-t). Cmin
and Cmax were defined as the minimum and maximum
observed concentrations, respectively. tmax was the time
at which Cmax was reached. AUC of the five conditions
were compared and analyzed by paired-samples t-tests.
A P-value< 0.05 was considered statistically significant.
Analyses were performed with the SPSS software pack-
age version 16.0 for Windows.
Results
Eight subjects (6 females and 2 males, aged 26.9 ±
5.9 years (mean ± SD), weighing 70 ± 4.3 kg, with a BMI
of 23.6 ± 1.3) completed the trial. No adverse events were
observed with both types of administration (i.e. pellets,
solution).
HPLC analysis of the whole blood showed that ATP
concentrations were stable over time, and that there
were no statistically significant differences between pla-
cebo and ATP supplements for any type of administra-
tion (data not shown). Of the other metabolites (ADP,
AMP, adenosine, adenine, inosine, hypoxanthine, and
uric acid), only uric acid concentrations changed in
response to supplement administration (Figure 1). Com-
pared to placebo, the uric acid AUC increased significantly
when ATP was administered by proximal-release pellets
(P=0.003) or by naso-duodenal tube (P=0.001). Adminis-
tration of ATP by distal-release pellets did not lead to a
significantly increased uric acid AUC, compared to pla-
cebo. The peak uric acid concentrations (Cmax) were 36%
higher (0.28 ± 0.02 mmol/L) for proximal-release pelletscompared to distal-release pellets (0.21 ± 0.01 mmol/L),
but 6% lower compared to the administration via naso-
duodenal tube (0.30 ± 0.02 mmol/L) (Figure 1 and statistics
in Table 1). The mean time to peak uric acid concentration
(tmax) was shorter for naso-duodenal tube administration
(tmax ranged from 75 to 195 min with mean ± SD 135±
15 min) as compared to the pellet administration (tmax
ranged from 150 to 390 min with mean ± SD 234±
32 min). An overview of the inter-subject variability in
uric acid concentrations following administration of
ATP (tube and pellets) is presented in Additional file 1:
Figure S1.
To verify whether the coating of the pellets had been
adequate, they were tested in a dissolution experiment.
Figure 2 shows the percentage of ATP that was released
from the pellets, either as ATP or as any of its metabo-
lites. After staying for 120 min in 0.1 N HCl, less than 5%
ATP (5.0± 0.6% for the proximal-release pellets and
3.4 ± 0.4% for the distal-release pellets) was released from
the pellets. Subsequent rapid changing of the buffer solu-
tions to pH 6.5 or 7.4 for 60 min caused a release of 50%
of the remaining ATP within 5 min (proximal-release pel-
lets) or 25 min (distal-release pellets), which increased to
>80% after 60 min. ATP was partially broken down to
ADP (8.6% for proximal-release pellets, 7.0% for distal-
release pellets), AMP (1.0 and 0.7%, respectively), and
uric acid (4.0 and 2.5%, respectively).
Finally, to investigate whether the timing of pellet dis-
integration in the gastrointestinal tract had been as
expected, plasma lithium concentrations were deter-
mined in samples collected for 7 h after administration
of the coated pellets (Figure 3). The three types of pellets
had different release profiles, as was quantified by meas-
uring the AUC (Table 1). Comparison of the AUC of the
two types of ATP-containing pellets revealed that the
proximal-release pellets caused a significantly higher in-
crease in plasma lithium than the distal-release pellets
(P= 0.001) (Figure 3). Further comparison of the prox-
imal-release pellets with or without ATP, showed that
the lithium AUC was significantly lower in the ATP-
containing pellets than in the placebo-containing ones
(P= 0.001). Individual plasma lithium concentrations are
depicted in Additional file 2: Figure S2. Lithium Cmax for
the proximal release pellets was reached between 135
and 210 min after administration at a mean concentra-
tion of 404 ng/mL for the placebo pellets and 200 ng/mL
for the ATP pellets. The highest plasma lithium concen-
tration (717 ng/mL) was measured in a volunteer receiv-
ing placebo proximal-release pellets. The distal-release
pellets, on the other hand, showed a delayed and lower
release profile, with lithium concentrations starting to
rise only approximately 240 min after administration,
while a maximum concentration of 103 ng/mL was
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Figure 1 Uric acid concentrations in healthy volunteers after oral ATP or placebo supplementation. A single dose of 5000 mg ATP or
placebo was administered via proximal-release pellets, distal-release pellets, or naso-duodenal tube. Data are presented as percentage increase
from the mean of three blood samples taken before administration. Values are means ± SEM, n= 8.
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The aim of this study was to determine the oral bioavail-
ability of ATP after targeted delivery to the small intes-
tine using two types of enteric coated pH-sensitive
multi-particulate supplements. As a comparison, ATP was
also directly instilled in the small intestine via a naso-
duodenal tube. Although the ATP dosage administered
in our study (5000 mg, or 55.6 - 83.3 mg/kg body weight)
exceeded those of most other oral administration studies,Table 1 Pharmacokinetic parameters for uric acid and lithium
Mode of administration (time period) AUC uric acid mmol.min/L
Naso-duodenal tube
ATP (270 min) 19.6 ± 4.4 a,b,c
Placebo (270 min) −0.4 ± 0.4
Proximal-release pellets
ATP (270 min) 16.1 ± 3.0
Placebo (270 min) 0.8 ± 0.9
ATP (420 min) 25.4 ± 5.7 d,e
Placebo (420 min) 0.9 ± 1.1
Distal-release pellets
ATP (270 min) 1.7 ± 1.1
ATP (420 min) 3.2 ± 1.4
Values are group means ± SEM, n= 8 per formulation, P-values are based on paired
a Different from naso-duodenal tube placebo (P=0.002), b Different from ATP distal
pellets 270 min (P=0.007) d Different from ATP distal release pellets 420 min (P=0.
from each other (P< 0.001).we observed no changes in whole blood ATP concentra-
tions. Recommended dosages to ‘increase your energy’ for
ATP supplements marketed on the internet usually range
from 100–250 mg per day, which is considerably lower
that the dosage we tested. The only other human study
that we know of that measured ATP after oral administra-
tion of either 150 mg or 225 mg ATP as enteric coated
beadlets, also found no increase in plasma and whole
blood ATP concentrations [6]. Kichenin et al. orallyafter oral administration of ATP
Cmax mmol/L (range) tmax min (range) AUC Lithium mmol.min
0.31 ± 0.03 135 n.a.
(0.23-0.38) (105–240)




0.30 ± 0.03 240 65174± 7985 f
(0.21-0.41) (165–390)
0.20 ± 0.02 n.a. 117914 ± 15021 f
(0.16-0.31)
n.a. n.a. n.a.
0.22 ± 0.02 390 12575± 2832 f
(0.17-0.34) (105–420)
-samples t-tests. N.a. = not available.
-release pellets 270 min (P= 0.007), c Different from proximal-release placebo
005), e Different from proximal-release placebo pellets (P= 0.005), f Different
Figure 2 Release of ATP and metabolites from enteric coated supplement after dissolution testing. Release of ATP and its metabolites as a
percentage of the release at 180 min for proximal-release pellets (closed symbols) and distal-release pellets (open symbols), after 120 min in 0.1 N
HCl, and subsequently 60 min in buffer solutions with either pH 6.5 (proximal-release pellets) or 7.4 (distal-release pellets). Data were obtained by
the reciprocating cylinder method (USP apparatus 3). Values are means ± SEM, n= 3.
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rabbits and up to 10 mg/kg per day to rats [10,11]. No
increases in systemic plasma or erythrocyte ATP concen-
trations were observed. However, the concentration of
ATP in plasma taken from the portal vein of rats increased
rapidly up to a 1000-fold after direct instillation of ATP in
the small intestine. In humans it is not possible to collect
portal vein blood without performing very invasive proce-
dures, and we could therefore not determine this is our
study. Intravenous ATP administration in humans ranging
in dosage from 36 to 108 mg/kg per day [13,18,19] did lead
to substantial increases in ATP concentration in the sys-


























Figure 3 Plasma lithium concentrations in healthy volunteers after ad
dose of 5000 mg ATP or placebo with 60 mg Li2CO3 was administered via
SEM, n= 8.metabolites considered, only uric acid concentrations
increased significantly after administration of the prox-
imal-release pellets and of the naso-duodenal tube, but
not of the distal-release pellets.
When ATP is released into the small intestine, ecto-
nucleotidase triphosphatase diphosphohydrolases present
on the luminal side of intestinal enterocytes dephosphor-
ylate ATP via ADP to AMP [20], after which ecto-5′-
nucleotidase (CD73) degrades AMP to adenosine [21]. In
mice, the terminal ileum is the site in the intestine with
the lowest ATPase activity [22]. Although information
on the human intestine is limited, this may explain the





ministration of supplement containing 60 mg Li2CO3. A single
proximal-release pellets or distal-release pellets. Values are means ±
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tive (CNT) and equilibrative (ENT) nucleoside transpor-
ters are able to transport nucleosides into the intestinal
enterocytes and to the capillary bed of the intestinal villi.
CNTs exhibit a proximal-distal gradient with highest
transport activities present in the jejunum [23]. Finally, ad-
enosine is taken up by the erythrocytes through ENTs in
the erythrocyte membrane [24]. In vivo studies in animals
and humans indicated that inside the erythrocytes adeno-
sine can be used for the synthesis of ATP [19]. In our
study, neither ATP nor adenosine concentrations were
increased, suggesting that instead of being used for ATP
synthesis in the erythrocytes, orally administered ATP is
degraded to uric acid by xanthine oxidase, an enzyme
which is expressed mainly in the liver and in endothelial
cells of blood vessels [25]. Assuming that uric acid is pri-
marily present in the extracellular fluid (the volume of
which is approximately 22% of body weight), that the
5000 mg ATP is completely broken down to 9.06 mmol
uric acid, and that there is no loss of uric acid due to ex-
cretion, the estimated ‘bioavailability’ of ATP (defined as
the observed uric acid increase as a percentage of the the-
oretical maximum) was 16.6± 2.3% for the naso-duodenal
tube, 14.9 ± 2.5% for the proximal-release pellets and
3.2 ± 0.6% for the distal-release pellets.
In our study, the increase in plasma uric acid concentra-
tion was similar for the proximal-release pellets and the
naso-duodenal tube, indicating complete release of ATP
from the pellets. The delay in uric acid increase of about
1 h following proximal-release pellet administration com-
pared to naso-duodenal tube administration is probably a
combined effect of gastric residence time and the time
needed for dissolution of the coating of the pellets. We
used enteric pH-sensitive coated pellets because they were
previously successfully used for the targeted delivery of
various compounds [26-28]. The pH-sensitive EudragitW
polymer coating provided sufficient gastroresistance, as
unwanted in vitro release of ATP from the pellets was
within the limits set by the USP (i.e. <10% drug release in
2 h in 0.1 N HCl) [29]. In vivo, the intestinal pH and tran-
sit times are the main factors determining the location
where each type of coating releases its contents. The
duodenum has a pH of 6.4 with a mean transit time to
the jejunum of 30 min, while in the ileum, the pH rises
to 7.4 with a transit time to the colon for pellet dosage
forms in fasted individuals of approximately 3 ± 1 h
(mean ± SD) [30-32]. The modest rise in uric acid con-
centration after ingestion of the distal-release pellets
may be partly caused by incomplete release in the small
intestine, in combination with the limited uptake of
ATP once it has entered the colon [33]. Timely release
of the contents of the pellets was confirmed by using
lithium as a marker. As expected from earlier studies in
which lithium was used as a marker [34], the lithiumdosage administered to the subjects was safe; the high-
est plasma lithium concentration amounted to only
17% of the lower therapeutical range advised for
patients with bipolar disease [35]. Remarkably, higher
lithium concentrations were reached after administra-
tion of the placebo pellets compared to ATP pellets.
Possibly, the higher content of carboxymethylcellulose
(CMC), which promotes pellet disintegration by expanding
upon contact with water, in the placebo pellets (nearly
100%), compared to the ATP pellets (nearly 50%), resulted
in a quicker release of lithium and hence the higher
plasma concentration. Another possibility is that the
negative charges on the CMC molecule, which promote
its exposure to water, are shielded by the sodium-ions in
the ATP pellets, thus slowing the swelling of CMC in
the pellets and thereby the release of their contents.
What may be the consequences of increased plasma
uric acid concentrations obtained by orally administering
ATP? On the one hand, hyperuricemia is a risk factor for
gout and is associated with hypertension [36-39]. The
highest individual uric acid concentration (405 μmol/L)
we observed, is within the range reported for male non-
gouty individuals (179–440 μmol/L) [40]. No adverse
effects were observed during the study. The short-lasting
increase in uric acid concentration found in the current
study is not likely to cause any symptoms of gout or
hypertension, since these require a prolonged period of
severe increase [41]. On the other hand, high uric acid
concentrations have also been associated with beneficial
health effects. Uric acid may function as an antioxidant
[42,43], and epidemiological studies have shown that
healthy subjects with high uric acid concentrations are at
a reduced risk for developing Parkinson’s disease, a con-
dition suspected to be instigated by oxidative damage
[44,45]. Furthermore, patients with multiple sclerosis are
known to have lower uric acid concentrations than
healthy volunteers, and raising the uric acid concentra-
tion by pharmacological means has been the subject of
recent investigation [46]. Although increasing the uric
acid concentration pharmacologically using ATP pellets
might have benefits for certain individuals, these have to
be weighed against increased risks of gout and possibly
cardiovascular disease [36,38,39].
Conclusions
A single dose of oral ATP supplement is not bioavailable,
whether administered as proximal-release or distal-release
enteric coated pellets, or directly instilled in the small-
intestine. This may explain why several studies did not
find ergogenic effects of oral ATP supplementation. An
on average 50% increase in uric acid concentration was
found with the proximal-release pellets and with the
naso-duodenal tube, suggesting that ATP or one of its
metabolites is absorbed, but immediately metabolized
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may have beneficial effects, but this needs further study.
Also, more studies are needed to determine whether
chronic administration of ATP will enhance its oral
bioavailability.
Additional files
Additional file 1: Figure S1. Individual increases in plasma uric acid
concentrations following supplementation with 5000 mg ATP. ATP
was administered at t = 0 as a solution through a naso-duodenal tube (A),
proximal-release pellets (B), or distal-release pellets (C). Values represent
the percentage increase from the mean baseline values that were
determined in three samples collected at 30, 20 and 10 min before
administration. The legend shows sex of subjects. Note the different scale
of the x-axis in panel A.
Additional file 2: Figure S2. Individual increases in plasma lithium
concentrations after administration of supplement containing
60 mg Li2CO3. Plasma lithium concentrations (ng/ml) of 6 female and 2
male volunteers after (A) proximal-release pellets containing ATP, (B)
proximal-release pellets containing placebo or (C) distal-release pellets
containing ATP.
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